

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of
Howard LEVIN et al
Serial No. 10/642,638



Atty. Ref.: 3659-70

Group: 3762

Filed: August 19, 2003 Examiner: DEAK, Leslie R.

For: METHOD AND APPARATUS FOR PERIPHERAL VEIN FLUID
REMOVAL IN HEART FAILURE

* * * * *

September 15, 2005

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98:

INFORMATION DISCLOSURE STATEMENT

- 1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**
[within 3 months of filing or prior to 1st Office Action] *N/C*
- 2. **Statement Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance] *N/C*
- 3. **Fee Payment Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance] *\$180.00*
- 4. **Statement & Fee Payment Pursuant to 37 CFR 1.97(d)**
[before Issue Fee payment] *\$180.00*

- 5. A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document is enclosed herewith.

This paper is submitted in accordance with:

- 6. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
- 7. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
- a) The Statement required by 37 CFR §§1.97(c)(1) and (e) made in item 9 below; or


00000069 10642638
09/19/2005 HAL111
01 FC:1806

- b) The fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 10 below.
- 8. 37 CFR §1.97(d): [before issue fee payment]; and
 - a) This is a request for consideration of the subject Information Disclosure Statement. The fee required by 37 CFR §1.17(p) is authorized in item 10 below; and
 - b) The Statement required by 37 CFR §§1.97(d)(1) and (e) is stated in item 9 below.
- 9. Statement under 37 CFR 1.97(e)
 - a) Each item of information contained in this Information Disclosure Statement was cited for the first time in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
 - b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
- 10. Please charge all applicable fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By:



Jeffrey H. Nelson
Reg. No. 30,481

JHN:glf
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

Sheet 1 of 1



INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Howard LEVIN et al

3659-70
APPLICANT

SERIAL NO.

5055-70

10/642,638

Howard LEVIN et al

FILED DATE

GROUP

August 19, 2003

3762

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

TRANSLATION

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

J.B. Gouyon et al, "Urea Removal By Neonatal Hemo(dia)filters In Hyperazotemic Rabbits", Intensive Care Med (1997) 23:677-683.

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)